Purpose: To measure the growth rate of microcystic subtype serous adenomas of the pancreas diagnosed by imaging. Methods: For this retrospective study, 241 imaging studies were reviewed from 1998 to 2005. Thirty-one patients met our strict diagnostic imaging inclusion criteria and had at least 18 months of imaging follow-up. Patient demographics and lesion imaging characteristics were tested as predictors of growth. Results: Growth was measured over a mean period of 42 months. There was a significant (P ¼ .0004) linear growth of tumour for the population. There was significant clustering (P ¼ .001) of the population into 2 growth rates: 0.50 mm/y (n ¼ 23) and 5.5 mm/y (n ¼ 8). The diameter of the lesion at presentation was significantly correlated with growth (r ¼ 0.45; P ¼ .01). Conclusion: The microcystic subtype of serous cystadenomas of the pancreas diagnosed with imaging criteria demonstrates 2 distinct and slow growth rates. The size of the lesion at presentation is correlated with growth rate.
[1e5]. Some investigators have advocated resection for all cystic neoplasms [6, 7] , whereas other investigators advocate a more selective approach [8e11]. The overwhelming majority of microcystic serous lesions of the pancreas are benign adenomas, with only a handful of case reports of serous cystadenocarcinomas [12, 13] . Imaging-based diagnostic criteria for serous cystadenomas have been demonstrated [14e17]. To our knowledge, only 1 previous study attempted to characterize the growth characteristics of serous cystadenomas [8] , and none has used strict imaging diagnostic criteria.
The purpose of our study was to retrospectively determine the growth rate of serous cystadenomas of the pancreas identified by strict diagnostic imaging criteria for the microcystic subtype, to evaluate subpopulations of growth, and to identify predictors of growth.
Methods
Institutional ethics research review board approval was obtained for this retrospective study; informed patient consent was not required. We searched our patient diagnostic imaging report database that contained data on all of the radiologic examinations performed and reported at our institution from January 1998 through November 2005 for patients with a possible diagnosis of serous cystadenomas of the pancreas (search terms: serous cystadenoma, cystic neoplasm, pancreatic cyst, microcystic). We identified 1141 patients. A cohort of 241 patients with a minimum of 18 months imaging follow-up with computed tomography (CT) or magnetic resonance imaging (MRI) of the pancreatic lesions was then selected.
All of the pancreatic imaging of these 241 patients was reviewed. Strict diagnostic imaging inclusion criteria for the microcystic type were applied: a patient was considered to have a serous cystadenoma if there was a cystic pancreatic lesion that contained 6 or more cysts, all cysts were smaller than 2 cm in size. Patients were excluded if there was communication of the lesion with the pancreatic duct, pancreatic-duct dilatation, or pancreatic calcifications outside of the lesion, because these findings could also be seen in intraductal papillary mucinous neoplasm or in chronic pancreatitis.
A total of 31 patients (14 men, 17 women; age range, 36e 82 years; mean age, 63 years) met the selection criteria and constituted our study population. We recorded 2 axis measurements of the pancreatic cystic lesion size for each imaging examination, lesion location in pancreas, enhancement pattern, cystic lesion calcification pattern, and number of cysts. The patient electronic clinical database was also reviewed for patient demographics, presenting symptoms, evidence of complication from pancreatic cystic lesion, comorbidities, and living status at time of termination of the study (November 17, 2006) . The patients and/or their family were also contacted at home if the clinical database information was incomplete. Clinical follow-up could be completed in 30 of 31 patients.
The original cohort of 1141 patients was cross-referenced to the operative lists. The imaging of these operated patients was reviewed to identify patients who would have met the imaging diagnostic criteria but would not have had long enough imaging follow-up to be included in the study. For any such cases, the pathology reports were reviewed.
Imaging Protocols
A variety of CT and MRI imaging protocols and equipment were used during the 7-year period. Helical CT with 4-, 8-, 16-, and 64-detector rows (GE Medical Systems, Waukesha, WI; Toshiba Medical Systems, Tustin, CA; Siemens Medical Solutions, Malvern, PA). Pancreatic CT imaging protocols (noncontrast, followed by 45-second arterial phase and 70e80-second portal venous phase intravenous contrast imaging) as well as routine abdominal CT protocols (70e80second portal venous phase intravenous contrast imaging) were the most commonly performed examinations. Slicethickness acquisition evolved during the study from 10e 2.5 mm. Abdominal MRI was performed on a 1.5 T system (GE Medical Systems). Exact sequences varied through the 7-year period but included T2-weighted rapid acquisition with refocused echoes (RARE) sequences in 2 planes, inand out-of-phase T1-weighted gradient-echo imaging, as well as dynamic 2-dimensional and 3-dimensional T1 gradient-echo fat-saturated gadolinium-enhanced imaging. Ultrasound examinations were performed on ATL 3500 and 5000 equipment (Philips Medical Systems, Bothwell, WA).
Statistical Analysis
Means and percentages were used as summary statistics for continuous and categorical variables. To summarize overall growth, a linear random effects model was fitted with the longest lesion length as the outcome time since initial imaging as the predictor and subject as the clustering variable [18] . The investigation that there are 2 groups of growth rates was done in 3 stages. First, a linear regression model was fitted to each subject to estimate the subject-specific rates of growth over time since initial imaging. Second, these subject-specific slopes were passed to mixture modelling software [19] to assess whether they came from a single population or whether they formed 2 clusters. The resulting analysis demonstrated that the slopes came from 2 clusters. For each slope, the probability was estimated that it came from a specific cluster. If the estimated probability that a subject's slope belonged to the slow-growing cluster was more than 50%, then a subject was classified as slow growing; otherwise, the subject was classified as fast growing. Comparisons of clinical and demographic characteristics between slow-growing and fast-growing subjects were made with the Fisher exact test or the 2-sample t test, as appropriate. Individual lesion growth profiles were checked graphically for linearity, and the fit of the mixture model to the entire data set was assessed by computing a pseudo-R 2 , the relative reduction in error variance between regression models with intercept only and with intercept plus slopes. All analyses were done in R 2.4.0 [20] .
Result

Patients Demographics
A summary of patient's demographics is presented in Table 1 . Seventeen of the 31 patients (55%) of our population were women. Their average age was 63 years. Twenty-four patients (77%) were still alive at the termination of the study. None of the 7 patients who died had their cause of death attributed to their pancreatic lesion. Eleven of the patients (35%) had another neoplastic diagnosis.
Presentation
Patient demographics at first imaging of their pancreatic serous cystadenoma are summarized in Table 1 . In total, 26 of 31 patients (84%) had their pancreatic lesions identified during imaging workup for symptoms or medical reasons unrelated to their pancreatic lesions. These included all 11 of the patients with other neoplastic diagnosis, 11 patients with abdominal imaging for other illnesses, 3 patients with biliary colic symptoms who had a pancreatic lesion incidentally discovered on abdominal ultrasound, and 1 patient with abdominal bloating. Five patients had symptoms that were unexplained by original imaging (epigastric and vague abdominal pain). All 5 of these patients had their symptoms resolve spontaneously in the few months after the first imaging examination.
Imaging Findings
The imaging findings are summarized in Table 2 . The majority of the serous cystadenomas were identified in the head of the pancreas: 14 of 31 (45%). The next mostcommon location was in the tail: 8 of 31 (26%). Ninetyfour percent of lesions demonstrated septal enhancement, whereas 6% demonstrated no enhancement. Ninety-four percent of lesions demonstrated no signs of calcification. The majority of lesions demonstrated greater than 9 cysts on at least 1 imaging study: 23 of 31 (74%).
Lesion Growth
The average follow-up was 42 months (range, 20e82 months). The best regression model was a linear growth model by using the longest measured diameter of the lesion (pseudo-R 2 ¼ 0.73). The average growth for the entire population was 1.70 mm/y (95% confidence interval, 0.9e 2.5; P ¼ .0001). The mixture model analysis demonstrated that the slopes were clustered into 2 different growth groups (P ¼ .0028). The distribution of the 2 separate groups is shown in Figure 1 . The majority of patients (n ¼ 23) were in the slower growth-rate group (mean growth rate, 0.50 mm/y; range, 1.9e2.9 mm/y). The faster growth-rate group (mean growth rate, 5.51 mm/y; range, 3.8e7.8 mm/y) had a smaller number of patients (n ¼ 8). The average lesion size for the faster growth-rate group was 4.26 cm (range, 1.7e6.8 cm; 
Predictors of Growth
By using the patient's clinical data and the imaging findings, we investigated variables related to growth. The analysis is summarized in Table 3 . The largest diameter of the lesion at presentation was positively correlated with growth rate by using a Pearson correlation coefficient of 0.45 (P ¼ .01) ( Figure 2 ). No other clinical and imaging characteristics were significantly associated with growth.
Operated Patients
In the main study cohort, 1 of 31 patients (a 39-year-old woman), in the fast-growing group, with a lesion size of 2.5 cm, underwent a Whipple duodenopancreatectomy. The final diagnosis was serous cystadenoma. Of the 1141 patients whose reports were reviewed, 103 underwent surgery, with fewer than 18 months of follow-up. None of these 103 patients met the imaging criteria for serous cystadenoma used in this study.
Discussion
Our study demonstrates serous cystadenomas that are defined by strict imaging criteria for the microcystic type had slow growth rates that could be divided into 2 separate populations. The vast majority of our studied population had an almost negligible rate of growth, but a smaller subset demonstrated slow linear growth. We demonstrated a significant correlation between largest diameter at presentation and rate of growth. In our study, the average growth rate of serous cystadenomas of the pancreas was 1.79 mm/y. In 2005, Tseng et al [8] established an average growth rate for cystic pancreatic lesions that was approximately triple the growth rate in our study (6.0 mm/y). There are a few potential explanations for this discrepancy. It is All P values come from the Wilcoxon rank sum test, with the exception of ''P,'' which come from testing the Pearson correlation against a value of zero. Figure 2 . Correlation of growth rate and longest diameter at presentation. Pearson covariate analysis demonstrates a significant correlation between growth rate and longest diameter at presentation (P ¼ .001; R ¼ 0.451). important to note that our study and the study by Tseng et al [8] differ in their inclusion criteria, and this could have had a significant impact on the growth-rate assessment. The Tseng study [8] included patients who had pathologic diagnosis of serous cystadenomas as well as patients with CT diagnosis consistent with serous cystadenomas or a small indeterminate cystic lesion of the pancreas, with no specification of the imaging criteria used. This may have resulted in the inclusion of cystic neoplasms other than microcystic tumours in their cohort. One might argue that, because we studied patients with a minimum of 18 months imaging follow-up, there was a bias towards slowergrowing tumours that would be less likely to undergo surgery in fewer than 18 months. However, none of the patients who met our imaging criteria were taken to surgery during the 18-month period after initial imaging. The 1 patient who underwent surgery after a minimum of 18 months' imaging follow-up had the expected diagnosis of serous cystadenoma. We believe that such a bias is unlikely to be present.
Our study population demographics was comparable with previously published populations of serous cystadenomas; previous average ages are reported from 61-68 years, with a slight female predilection and a location in the uncinate, head, and neck of the pancreas in 44%e53% [7, 8, 21] . The size of tumours in our study was smaller than reported in prior studies. The first large series of pathologically proven serous cystadenoma was first described in 1978 [21] . This group had an average lesion size of 10.8 cm, and 29% of the patients were asymptomatic. In 1992, another review of pathologically proven serous cystadenomas [7] had an average lesion size of 6e7.5 cm, and 31% of the patients were asymptomatic. The study by Tseng et al [8] had an average lesion size of 4.9 cm, and 53% of all tumours were incidentally discovered. The average lesion size in our study is the smallest reported to date (2.7 cm). Almost all of the lesions were identified incidentally, and 68% of the patients had no symptoms that could be attributed to the pancreatic lesions. The identification of smaller lesions in asymptomatic patients may reflect the increased utilisation of There were some limitations in our study. Our patient population was small, in part, secondary to our strict diagnostic imaging inclusion criteria and, in part, secondary to the minimum length of imaging follow-up required to participate. Although this raised our confidence of the studied lesions, it has limited our statistical power and allowed us to only identify 1 significant predictor of growth. The imaging protocols have evolved over the 8 years of inclusion criteria. Thinner CT slice thickness and improved MRI over the length of the study may have improved lesion characterization, such as assessment of the number of cysts in the lesions, and lesion measurements. Some true serous cystadenomas may have been excluded in the early years of the study because of poorer image resolution and the inability to discern a sufficient number of cysts to meet our inclusion criteria.
Cystic lesions of the pancreas are increasingly identified incidentally with increased cross-sectional imaging utilisation [1] . Published recommendations for the management of these lesions vary [1e5, 10, 11] . The majority of tumours exhibit negligible growth. Those lesions that do grow usually grow slowly (<8 mm/y). Because none of the patients in this study had mortality associated with lesion growth, this study supports the practice of follow-up imaging for patients, with strict imaging criteria applied for the diagnosis of serous cystadenoma. Further long-term prospective studies would be required to validate this approach and to better clarify the optimal imaging modality and frequency. In conclusion, serous cystadenomas identified by strict diagnostic imaging criteria for the microcystic subtype can demonstrate a negligible or a faster rate of growth, with the size of the lesion at first presentation being a predictor of growth. 
